Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.